FDA has approved Celgene Corporation’s OTEZLA® (apremilast) an oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis. A chronic disorder, psoriatic arthritis is characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and a decrease in physical functioning. OTEZLA is the only FDA-approved oral treatment for psoriatic arthritis, according to Celegene.   

The drug is expected to be available in the United States in March 2014 and will be dispensed through a network of specialty pharmacies, according to the company.

Sources: Celgene Corporation and FDA